ChiCTR2600115884
尚未开始
/
/
/
2026-01-03
/
/
Type 2 diabetes
Effectiveness of acceptance-based diabetes self-management (ACT-DSM) for adults with type 2 diabetes for improving diabetes distress and glycaemic control: A randomised controlled trial
Effectiveness of acceptance-based diabetes self-management (ACT-DSM) for adults with type 2 diabetes for improving diabetes distress and glycaemic control: A randomised controlled trial
The primary objective is to determine whether the ACT-DSM programme is more effective than conventional diabetes self-management education in reducing HbA1c over 3–12 months. The secondary objective is to assess its impact on diabetes distress, self-care, self-efficacy, psychological flexibility, and other health markers from 1 week to 12 months post-intervention. This is tested in a cluster randomised controlled trial involving adults with type 2 diabetes of ≤8 years duration, suboptimal glycaemic control (HbA1c ≥7%), and moderate-to-high diabetes distress.
整群随机分组
其它
Six Hospital Authority general outpatient clinics are randomised (1:1) to ACT-DSM or control group using computer-generated random sequence by an independent statistician. The Principal Investigator (PI) and research team are not involved in generating the sequence. Allocation is concealed using sealed opaque envelopes.
Outcome assessor (RA2) is blinded to group allocation.
Health and Medical Research Funding
/
108
/
2026-01-02
2026-07-31
/
Hong Kong Chinese resident Aged 18–64 years Diagnosed with type 2 diabetes (T2D) for ≤8 years HbA1c >=7.0% in the past 3 months and confirmed at baseline capillary testing At least moderate diabetes distress: mean item score >2 on the Chinese Diabetes Distress Scale (CDDS-15) Able to communicate in Cantonese or Mandarin；
请登录查看Has a mental disorder such as: Major depression Psychosis Has an acute or severe medical illness Currently receiving or has recently received a psychological intervention for diabetes self-care；
请登录查看The Chinese University of Hong Kong
/
GLP1减重宝典2026-01-10
良医汇肿瘤资讯2026-01-10
易慕峰2026-01-10
医药笔记2026-01-10
信立泰药业2026-01-10
Medactive2026-01-10
兽药资讯2026-01-10
药时空2026-01-10
德睿智药2026-01-10
丁香园 Insight 数据库2026-01-10
400-9696-311 转1
400-9696-311 转2
400-9696-311 转3
400-9696-311 转4
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息
友情链接: 摩熵医药 摩熵医药企业版 摩熵化学MolAid 晓材Matmole 摩熵医学MedXYZ 载体质粒 觅健肿瘤互助 动脉网 药物百科 中国医疗人才网 医药招商网
